Catalog No.S1070

PHA-665752 Chemical Structure

Molecular Weight(MW): 641.61

PHA-665752 is a potent, selective and ATP-competitive c-Met inhibitor with IC50 of 9 nM in cell-free assays, >50-fold selectivity for c-Met than RTKs or STKs.

Size Price Stock Quantity  
USD 70 In stock
USD 120 In stock
USD 470 In stock
USD 997 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 36 Publications

Purity & Quality Control

Choose Selective c-Met Inhibitors

Biological Activity

Description PHA-665752 is a potent, selective and ATP-competitive c-Met inhibitor with IC50 of 9 nM in cell-free assays, >50-fold selectivity for c-Met than RTKs or STKs.
c-Met [1]
(Cell-free assay)
RON [1]
(Cell-free assay)
Flk1 [1]
(Cell-free assay)
9 nM 68 nM 200 nM
In vitro

PHA-665752 significantly inhibits c-Met kinase activity with Ki of 4 nM, and exhibits >50-fold selectivity for c-Met compared with various tyrosine and serine-threonine kinases. PHA-665752 potently inhibits the HGF-stimulated c-Met autophosphorylation with IC50 of 25-50 nM. PHA-665752 also significantly blocks HGF- and c-Met-dependent functions such as cell motility and cell proliferation with IC50 of 40-50 nM and 18-42 nM, respectively. In addition, PHA-665752 potently inhibits HGF-stimulated or constitutive phosphorylation of mediators of downstream of c-Met such as Gab-1, ERK, Akt, STAT3, PLC-γ, and FAK in multiple tumor cell lines. [1] PHA-665752 inhibits cell growth in TPR-MET-transformed BaF3 cells with IC50 of <60 nM, and inhibits constitutive cell motility and migration by 92.5% at 0.2 μM. Inhibition of c-Met by PHA665752 (0.2 μM) also induces cell apoptosis of 33.1% and G1 cell cycle arrest with cells in G1 phase increasing from 42.4% to 77.0%. PHA665752 can cooperate with rapamycin to inhibit cell growth of TPR-MET-transformed BaF3 cells and non-small cell lung cancer H441 cells. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-SNU-5 M1zMc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3Xd5FKSzVyPUCuNVI{PzVizszN NUDkSGR1W0GQR1XS
LB2241-RCC MkLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4mz[WlEPTB;MD6xOVcxOiEQvF2= NWe2fHJXW0GQR1XS
KINGS-1 M3\tdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;YXWZPUUN3ME2wMlM2QTFzIN88US=> MmLqV2FPT0WU
MV-4-11 NXnWPHBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV73T2VbUUN3ME2xMlI6PDdizszN Mnf5V2FPT0WU
ES1 NW\4d5l5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LTSWlEPTB;Mz6zOFg3PiEQvF2= M{exO3NCVkeHUh?=
NOS-1 MnTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmqzTWM2OD12LkO5PFY4KM7:TR?= MljTV2FPT0WU
KM12 NXuwOmR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTRwNEG4JO69VQ>? M2r2N3NCVkeHUh?=
Becker M{DUXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjMVVJ6UUN3ME21MlI1PjZizszN MYnTRW5ITVJ?
NCI-SNU-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4S3NWlEPTB;NT62N|c{OyEQvF2= MoXMV2FPT0WU
EW-22 NV32NI46T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn65TWM2OD15LkezOlE1KM7:TR?= M4PvcHNCVkeHUh?=
A498 MnvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRThwMki0OFYh|ryP NEnZcG9USU6JRWK=
CTV-1 NVv4dI5uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPETWM2OD17Lki1NFI1KM7:TR?= NYnxb3F2W0GQR1XS
ETK-1 NIexb3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mof3TWM2OD1zMD6yPVMyKM7:TR?= MX7TRW5ITVJ?
NCI-H1395 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkf0TWM2OD1zMD64NFI1KM7:TR?= NVvK[|lqW0GQR1XS
HT-144 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmqwTWM2OD1zND6yNVY{KM7:TR?= MVfTRW5ITVJ?
NALM-6 M3Xie2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nmTGlEPTB;MUWuNlE6PiEQvF2= M3f4dnNCVkeHUh?=
KNS-81-FD M2nWdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWS2d4NZUUN3ME2xOU42QDR7IN88US=> NH;LVXJUSU6JRWK=
TE-15 NVK4WIg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TwS2lEPTB;MU[uOVc4OSEQvF2= NXrESnh3W0GQR1XS
SCC-15 NHnpdGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonuTWM2OD1zOD6zOFk5KM7:TR?= NHnqcppUSU6JRWK=
EoL-1-cell MmD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTF6LkS1OFUh|ryP MXvTRW5ITVJ?
NCI-H720 NWDvOYx7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jkd2lEPTB;MUiuO|cyKM7:TR?= MYHTRW5ITVJ?
KE-37 MkH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\RfWJKSzVyPUG5MlgzOzNizszN MYrTRW5ITVJ?
LXF-289 M2S4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfuTWM2OD1zOT64OlI6KM7:TR?= MlW2V2FPT0WU
RPMI-8402 M4PZTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvCTWM2OD1{MD6zNlY6KM7:TR?= M4TiT3NCVkeHUh?=
ACN Mk[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XDZ2lEPTB;MkKuNlQ6PyEQvF2= NX[0e4ZJW0GQR1XS
TE-11 NFnKNJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXLSG1rUUN3ME2yOk4xPjlizszN M1rVeHNCVkeHUh?=
COLO-800 NUjhc2pbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DaO2lEPTB;MkeuNVch|ryP MY\TRW5ITVJ?
MOLT-13 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XwVWlEPTB;MkeuNVg1PyEQvF2= NV;IeHpbW0GQR1XS
697 M4Xk[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTJTWM2OD1{OD63OlM{KM7:TR?= NGL4cGdUSU6JRWK=
VA-ES-BJ NIPBR5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2K4[2lEPTB;MkmuN|czQSEQvF2= M3zVb3NCVkeHUh?=
EW-13 M3Pv[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TMRmlEPTB;MkmuOVA1PSEQvF2= MY\TRW5ITVJ?
NB7 M3rCeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTN{LkK2OlUh|ryP NIDERVVUSU6JRWK=
MONO-MAC-6 NH6yb3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\VTWM2OD1|Mj64O|k2KM7:TR?= NIX4eWRUSU6JRWK=
SW962 M1XFbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHC[YVKUUN3ME2zN{41PTF|IN88US=> Mk\UV2FPT0WU
KS-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTrdGp5UUN3ME2zN{46PDhzIN88US=> MoC0V2FPT0WU
KU812 M3vlWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfDNpVKSzVyPUO0MlU4ODJizszN NXXwNmFVW0GQR1XS
BC-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nYfGlEPTB;M{iuNFM{KM7:TR?= Moi2V2FPT0WU
NCI-H510A MlTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33XTGlEPTB;M{iuNlA{OiEQvF2= M1HIXHNCVkeHUh?=
EW-18 NHTl[oRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3f4WmlEPTB;NECuPFMxOyEQvF2= NVHyWHlDW0GQR1XS
CCRF-CEM NFLacm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTR{LkK3PVch|ryP MlnFV2FPT0WU
HH MljmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXOd|FKSzVyPUSzMlUxPjlizszN MYLTRW5ITVJ?
NCI-H2171 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnCdGV5UUN3ME20Ok4xOjd{IN88US=> Ml62V2FPT0WU
LC-2-ad NGjUU2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3kN4ZRUUN3ME20PU4yPDF|IN88US=> Mn;IV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Administration of PHA-665752 induces a dose-dependent tumor growth inhibition of S114 xenografts by 20 %, 39% and 68%, at dose of 7.5, 15, and 30 mg/kg/day, respectively. [1] PHA665752 treatment significantly reduces the tumor growth of NCI-H69, NCI-H441 and A549 in mouse xenografts by 99%, 75%, and 59%, respectively. PHA665752 also significantly inhibits angiogenesis by >85%, due to decreasing the production of vascular endothelial growth factor and increasing the production of the angiogenesis inhibitor thrombospondin-1. [3]


Kinase Assay:[1]
+ Expand

In vitro enzyme assay:

The c-Met kinase domain GST-fusion protein is used for the c-Met assay. The IC50 value of PHA-665752 for the inhibition of c-Met is based on phosphorylation of kinase peptide substrates or poly-glu-tyr in the presence of ATP and divalent cation (MgCl2 or MnCl2 10-20 mM). The linear range (i.e., the time period over which the rate remains equivalent to the initial rate) is determined for c-Met, and the kinetic measurement and IC50 determination are performed within this range.
Cell Research:[1]
+ Expand
  • Cell lines: S114, GTL-16, NCI-H441, and BxPC-3
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 18, or 72 hours
  • Method: For proliferation assays, cells are grown in medium with 0.1% FBS for 48 hours after which they are treated with various concentrations of PHA-665752 in HGF (50 ng/mL) in a medium containing 2% FBS. After 18 hours, cells are incubated with BrdUrd for 1 hour, fixed, and stained with anti-BrdUrd peroxidase-conjugated antibody, and plates are read at 630 nm. For apoptosis assays, cells are grown in medium with 2% FBS in presence and absence of HGF (50 ng/mL) and various concentrations of PHA-665752 for 72 hours. After 72 hours, a mixture containing ethidium bromide and acridine orange is added, and apoptotic cells (bright orange cells or cell fragments) are counted by fluorescence microscopy.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Female athymic mice (nu/nu) bearing S114 or GTL-16 tumor xenografts
  • Formulation: Formulated in vehicle (L-lactate (pH 4.8) and 10% polyethylene glycol)
  • Dosages: ~30 mg/kg/day
  • Administration: Injection via bolus i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 128 mg/mL (199.49 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+castor oil
For best results, use promptly after mixing.

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 641.61


CAS No. 477575-56-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I need to use S1070 for intraperitoneal application in mice. Could you tell me the solvent you use, please?

  • Answer:

    The highest concentration of PHA-665752 (S1070) in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O is 5mg/ml. If you want to get higher concentration, the concentration of DMSO and PEG will be higher. For example, it can be dissolved in 8% DMSO+50% PEG 300+5% Tween 80+ddH2O at 10mg/ml clearly.

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

Related c-Met Products

Tags: buy PHA-665752 | PHA-665752 supplier | purchase PHA-665752 | PHA-665752 cost | PHA-665752 manufacturer | order PHA-665752 | PHA-665752 distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID